Current clinical development in HER2+ BC includes studies of antibody–drug conjugates [76], tyrosine kinase inhibitors [77], PI3K inhibitors [78], and vascular endothelial growth factor inhibitors [79], whilst next-generation oral SERDs are being investigated in ER+ BC [80–91]. The gene discussed is VEGFA; the disease is breast cancer.